2008 french national guidelines for the treatment of venous thromboembolism in patients with cancer: Report from the working group

被引：66

作者：

Farge, Dominique ^{[1
,2
,3
]}

Bosquet, Lise

Kassab-Chahmi, Diana

Mismetti, Patrick ^{[4
]}

Elalamy, Ismail ^{[5
]}

Meyer, Guy ^{[6
]}

Cajfinger, Francis ^{[7
]}

Desmurs-Clavel, Helene ^{[8
]}

Elias, Antoine ^{[9
]}

Grange, Claire ^{[10
]}

Hocini, Hamid

Legal, Gregoire ^{[11
]}

Mahe, Isabelle ^{[12
]}

Quere, Isabelle ^{[13
]}

Levesque, Herve ^{[14
]}

Debourdeau, Philippe ^{[15
]}

机构：

[1] Natl Canc Inst, Dept Recommandat, F-92513 Boulogne, France

[2] Hop St Louis, Serv Med Interne & Pathol Vasc, AP HP, Paris, France

[3] Univ Paris 07, INSERM, U976, F-75221 Paris 05, France

[4] Hop Nord St Etienne, St Etienne, France

[5] Hop Tenon, F-75970 Paris, France

[6] Hop Georges Pompidou, Paris, France

[7] Hop La Pitie Salpetriere, Paris, France

[8] Hop Edouard Herriot, Lyon, France

[9] Hop Font Pre, Toulon, France

[10] Hop Lyon Sud, Lyon, France

[11] Hop Cavale Blanche, Brest, France

[12] Hop Louis Mourier, F-92701 Colombes, France

[13] Hop St Eloi, Montpellier, France

[14] Hop Bois Guillaume, Rouen, France

[15] Hop Armees Desgenettes, Lyon, France

来源：

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY | 2010年 / 73卷 / 01期

关键词：

Cancer; Clinical practice guidelines; Low-molecular-weight heparins; Thrombolytics; Unfractionated heparin; Vena cava filters; Venous thromboembolism; Vitamin K antagonists; MOLECULAR-WEIGHT HEPARIN; DEEP-VEIN THROMBOSIS; VENA-CAVAL FILTERS; HIGH-GRADE GLIOMAS; PULMONARY-EMBOLISM; UNFRACTIONATED HEPARIN; ORAL ANTICOAGULANTS; ANTITHROMBOTIC THERAPY; SECONDARY PREVENTION; MALIGNANT-DISEASE;

D O I：

10.1016/j.critrevonc.2008.12.004

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Venous thromboembolism (VTE) is a major therapeutic issue in cancer patients. Advances in this field and heterogeneities in clinical practices prompted us to establish guidelines in the management of WE in cancer patients according to the SOR (Standards, Options and Recommendations) methodology. A literature review of the studies published on this topic between 1999 and 2007 was performed. The guidelines were developed from the analysis of 38 out of 418 publications selected. They were peer-reviewed by 65 independent experts. The treatment of WE in patients with cancer, including those with intracranial malignancies, should be based on low-molecular-weight heparins administered at therapeutic doses for at least 3 months. In the event of recurrent VTE, pulmonary embolism with hemodynamic failure or contra-indication to anticoagulant treatment, the indications and usages of vena cava filters and thrombolytic drugs should be the same as in non-cancer patients. (C) 2009 Dominique Farge. Published by Elsevier Ireland Ltd. All rights reserved.

引用

页码：31 / 46

页数：16

共 71 条

[21]

DHAMI MS, 1993, THROMB HAEMOSTASIS, V70, P393

[22] A meta-analysis comparing low-molecular-weight heparins with unfractionated heparin in the treatment of venous thromboembolism -: Examining some unanswered questions regarding location of treatment, product type, and dosing frequency [J].